SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that the Company will present at three upcoming investor conferences:
http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO
Live webcasts of all three presentations can be accessed at http://www.favrille.com. Replays will be available approximately one hour after each presentation and archived for one month.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company’s lead product candidate, FavId, is based upon unique genetic information extracted from a patient’s tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.
CONTACT: Pete De Spain, Director, Investor Relations & Corporate
Communications of Favrille, Inc., +1-858-526-2426, pdespain@favrille.com
Web site: http://www.favrille.com/
